'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment
(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results from an early...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.